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ABSTRACT
Hump­nosed pit vipers (Genus Hypnale) are venomous snakes from South India and Sri Lanka. Envenoming 
by Hypnale species may cause significant morbidity and is characterized by local envenoming and less com­
monly coagulopathy and acute renal failure. Currently there are three nominal species of this genus: H. hypnale, 
H. zara and H. nepa. This study investigates the biochemical and pharmacological properties of the venoms 
from the three Hypnale species in Sri Lanka. The three Hypnale venoms had similar chromatographic profiles 
using reverse phase high performance liquid chromatography and fractions with procoagulant activity were 
identified. Hypnale venoms had potent cytotoxicity in cultured rat aorta smooth muscle cells with similar IC50 
values. The venoms had weak neurotoxic and myotoxic activity in the isolated chick biventer muscle prepara­
tion. They had mild procoagulant activity with close MCC5 values and also phospholipase activity. Locally 
available polyvalent antivenom did not neutralise any venom effects. The study demonstrates that the three 
Hypnale venoms are similar and cytotoxicity appears to be the most potent effect, although they have mild 
procoagulant activity. These findings are consistent with clinical reports.
INTRODUCTION
Hump­nosed  pit­vipers  of  the  genus  Hypnale  are  medi­
cally  important  snakes  and  cause  between  22  and  77% 
of all snake bites in India and Sri Lanka (De Silva, 1981; 
Seneviratne et al, 2000). Although death is rare (Ariaratnam   
et al, 2008), H. hypnale is listed as a snake of category 1 
of medical importance by the World Health Organisation 
(World Health Organisation, 2010). This is because it is 
common, widespread and responsible for snakebite result­
ing in significant morbidity, disability and rarely mortality. 
However, little is known about the venom of this snake and 
no antivenom has been developed to treat envenoming by 
Hypnale species.
Recent taxonomic revision has led to changes in the spe­
cies comprising the genus. Maduwage et al, (2009) showed   
H.  hypnale  to  be  widespread  throughout  the  lowlands 
(<600m a.s.l.) of Sri Lanka and the Western Ghats moun­
tains that border the west coast of the Indian peninsula. 
However, two other species in the genus are restricted to   
Sri Lanka: H. nepa to the central highlands above 1,250m 
a.s.l, and H. zara to the rainforests of the island’s south­
western lowlands. Previously, it was thought that all cases 
of Hypnale envenoming were from a single species and it is 
unclear if there are differences between the species in their 
venom composition and clinical manifestations.
The  clinical  effects  of  Hypnale  envenoming  have  been 
studied only for the single species, H. hypnale. The most 
commonly reported effects include local pain and swelling, 
local  haemorrhagic  blistering,  regional  lymphadenopathy 
and rarely severe local necrosis and gangrene (Kularatne 
and Ratnatunga, 1999; Joseph et al, 2007; Ariaratnam et al,   
2008; Ariaratnam  et  al,  2009).  Systemic  effects  are  less 
common  and  include  non­specific  symptoms  (headache, ©The Author(s) | Journal of Venom Research | 2011 | Vol 2 | 17-23 | OPEN ACCESS  18
experiments using re­calcified plasma. Innovin was obt­
ained from Siemens. For phospholipase assay, the Cayman 
kit #765001 was used. Polyvalent antivenom (Bharat Serums 
and Vaccines Limited, India [Lot # LY62/05]) containing 
lyophilised  polyvalent  immunoglobulins  [F(ab’)2]  raised 
against Indian Cobra (Naja naja), Russell’s viper (Daboia 
russellii), Indian krait (Bungarus caeruleus) and Saw­scaled 
viper (Echis carinatus) was used for antivenom experiments 
because this is one of the antivenoms available in regions 
where these snakes occur. The amount of antivenom was   
based on that required to neutralize Russell’s viper venom 
because it is a large viper which has procoagulant effects. 
The  packaging  states  that  1ml  of  reconstituted  solution 
neutralizes 0.60mg of Russell’s viper venom.
Protein assay
Stock venom solutions were filter­sterilized using a 0.22μm 
Millipore  membrane  and  the  protein  content  determined 
using  a  BCA  protein  assay  kit  (Pierce;  Illinois,  USA), 
according to manufacturer’s instructions. Briefly, 25μl of 
venom diluted 2 and 5 fold in Milli­Q was put in triplicate 
on a 96­well micro­titre plate. BSA solutions diluted from   
1  to  0.025mg/ml  were  used  as  reference  standards  and 
Milli­Q used as the blank. Absorbance was measured at 
562nm utilizing the fusion α­plate reader (PerkinElmer., 
Massachusetts, USA).
Treatment of venom with the phospholipase A2 
inhibitor, p-Bromophenacyl bromide (pBPB)
A solution of H. hypnale venom (400μg) was prepared in 
TBS (4ml). pBPB (100μg) in ethanol (20μl) was added to 
half of the solution and ethanol (i.e., vehicle control) was 
added to the remaining portion. The venom solutions (with 
and without pBPB) were allowed to stand at room tempera­
ture for 20hr and then transferred to dialysis tubing (mwco 
12000). The dialysis tubes were placed in TBS (200ml) and 
stirred for 90min and the TBS buffer was replaced once 
during that time. These solutions were then utilized in the 
clotting and sPLA2 assays (see below). TBS (the buffer) 
was replaced once during that time.
Reverse phase high performance liquid  
chromatography (RP-HPLC)
RP­HPLC profiles for the three venoms were obtained using 
a Phenomenex Jupiter C18 column (5u 300A 250x4.6mm) 
with mobile phase 15% acetonitrile containing 0.1% trif­
luoracetic acid, increasing to 70% acetonitrile by t=100min, 
at a flow rate of 0.5ml/min.
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)
Twenty­five  μg  venom  was  diluted  in  Laemmli’s  sample 
buffer (50%, v/v, glycerol; 0.5%, w/v, bromophenol blue; 
3.1%, v/v, Tris­HCl pH 6.8, 0.05%, w/v, b­mercaptoethanol)   
at equal volumes [1:1 (v/v)] before heating for 5 min at 
95°C.  Proteins  were  loaded  on  a  12%  SDS­PAGE  gels 
[40% (v/v)] of 30% acrylamide monomer solution 375mM 
Tris­HCl pH 8.8; 0.1% (w/v) SDS, 0.1% (v/v) TEMED; 
0.05% (w/v) ammonium persulfate with 4% stacking gel 
13.2% (v/v) of 30% acrylamide monomer, 125mM Tris­
HCl pH 6.8; 0.1% (w/v) SDS; 0.05% (v/v) TEMED 0.05% 
(w/v) ammonium persulfate; Gels were placed in a Mini­ 
PROTEAN 3 system (Bio­Rad, CA, USA) containing run­
ning buffer (25mM Tris­base, 192mM Glycine, 0.1% (w/v) 
nausea,  vomiting  and  abdominal  pain),  nephrotoxicity, 
coagulopathy, thrombocytopenia and spontaneous haemor­
rhage (Kularatne and Ratnatunga, 1999; Joseph et al, 2007; 
Ariaratnam et al, 2008). There is one report of ptosis from 
envenoming by H. hypnale and no reports of myotoxicity.
H. hypnale was one the first snakes for which the patho­
physiology of envenoming was scientifically studied (Davy, 
1821). Davy reported local swelling, deep ulcerations and 
bloody stool based on envenoming in dogs, chickens and 
a  frog.  He  concluded  that  the  action  of  the  venom  was 
mainly local and inflammatory, which are observations that 
have been confirmed in more recent studies (Joseph et al, 
2007). However, there have been few further attempts to 
characte  rize Hypnale venom. De Silva et al (1994) showed 
the venom of H. hypnale had procoagulant, fibrinolytic and 
weak platelet­aggregation activity. Wang et al (1999) puri­
fied a phospholipase A2 from H. hypnale venom and isolated 
several isoforms of which W6a and W6b showed strong 
heparin­binding affinity and caused oedema in rat paws.
The aim of the current study was to investigate the bio­
chemical  and  pharmacological  properties  of  the  venoms 
from the three Hypnale species ­ H. hypnale, H. nepa and 
H. zara. In addition, it examined the effect of Indian poly­
valent antivenom against the bioactivity of the venoms.
MATERIALS AND METHODS
Venom collection, preparation and storage
Venom  was  collected  from  each  Hypnale  species  in  Sri 
Lanka as follows: H. hypnale (five specimens) from Galle 
(06º03’N, 80º12’ E), H. nepa (ten specimens) from Agrap­
athana (06º50’N, 80º40’ E) and H. zara (four specimens) 
from Kottawa (06º06’N, 80º20’ E). The crude venom was 
desiccated using dehydrated silica gel with the venom being 
allowed to come into contact only with polyethylene materi­
als. For cell proliferation assays and chick biventer cervicis 
nerve­muscle preparations stock solutions of venom pre­
pared as 1 or 2mg/ml in Milli­Q water were stored at ­20°C 
until required. For high performance liquid chromatography 
(HPLC), in­vitro coagulation and phospholipase A2 assays 
stock venom solutions were prepared as 1 or 2mg/ml in 50% 
glycerol, and stored at ­20°C.
Drugs and reagents
The following drugs and chemicals were purchased from 
Sigma (St Louis, MO, USA) acetylcholine chloride, car­
bamylcholine  chloride  (carbachol),  Dulbecco’s  modified 
Eagles Medium, high glucose (DMEM), Dulbecco’s phos­
phate  buffered  saline  (magnesium,  calcium  free),  foetal 
bovine  serum,  penicillin/streptomycin  and  p­bromophen­
acyl bromide (pBPB). Trypsin was purchased from SAFC 
biosciences  (Victoria,  Australia).  Tubocurarine  chloride 
was purchased from Calbiochem (San Diego, CA, USA). 
All stock solutions were made up in distilled Milli Q water. 
Fresh frozen plasma was obtained from the Australian Red 
Cross and aliquots of 10ml were thawed at 37°C. Tris­buff­
ered saline (TBS) consists of Tris (hydroxymethyl) meth­
ylamine (25mM) with NaCl (137mM) and KCl (3.4mM), 
adjusted to pH 7.4 with HCl and filtered through a 0.45μm 
membrane. 50μl calcium chloride (0.4M) was added per   
ml of plasma immediately prior to clotting studies for ©The Author(s) | Journal of Venom Research | 2011 | Vol 2 | 17-23 | OPEN ACCESS  19
washed three times with pre­warmed PBS and 50μl of fresh 
culture  media  and  10μl  of  MTS  solution  were  added  to 
each well. The plates were further incubated at 37°C with 
5% (v/v) CO2 for 3hr. Absorbance was measured at 492nm 
utilizing fusion α plate reader (PerkinElmer) as described 
above. Culture media supplemented with antivenom at the 
varying concentrations was also incubated with MTS, simi­
lar to media blanks, to ensure the antivenom does not elicit 
a change in absorbance readings.
Chick biventer cervicis nerve-muscle preparation
Chicks (4­10 days old) were killed by CO2 and exsanguina­
tion. The biventer cervicis nerve­muscle was dissected and 
mounted under 1g tension in 5ml organ baths containing 
physiological salt solution (NaCl 118.4mM; KCl 4.7mM; 
MgSO4 1.2mM; KH2PO4 1.2mM; CaCl2 2.5mM; NaHCO3 
25mM and glucose 11.1mM) at 34°C, bubbled with carbogen   
(95%,  v/v,  O2;  5%,  v/v,  CO2).  Indirect  twitches  of  the 
preparation  were  evoked  by  electrical  stimulation  of  the 
motor nerves using a Grass S88 stimulator (0.2ms, 0.1 Hz, 
supramaximal V). Blockade of twitches by the addition of 
d­tubocurarine  (10μM)  confirmed  the  selective  stimula­
tion of the motor nerves. The preparation was then washed 
until twitches were re­established. In the absence of electri­
cal stimulation, responses to acetylcholine (ACh, 1mM for 
30sec), carbachol (CCh, 20μM for 60sec) and KCl (40mM 
for 30sec) were obtained. The preparation was washed thor­
oughly, electrical stimulation recommenced and the prepa­
ration allowed to equilibrate for 30min. Venoms (10μg) were 
added to the organ bath and twitch height was recorded for 
1hr or until twitches were abolished. Contractile responses 
to ACh, CCh and KCl were obtained (as described above)   
at the conclusion of the experiment. In experiments exam­
ining the myotoxic effects of venom, the biventer cervicis 
muscle was directly stimulated every 10sec with pulses of 
2ms duration at supramaximal voltage. In these experiments 
the electrodes were placed around the belly of the muscle 
and d­tubocurarine (10μM) remained in the organ bath for 
the duration of the experiment. Venom was left in contact 
with the preparation until twitch blockade occurred, or for a 
3hr period. Venom was considered to be myotoxic if it inhi­
bited direct twitches or caused a contracture of the skeletal 
muscle.
In vitro coagulation assay
In vitro coagulation was performed using a turbidimetric 
assay as previously described (O'Leary and Isbister, 2010). 
In brief, venom dilutions in TBS (100μl) were placed in 
microtitre plate wells at 37°C and then re­calcified plasma 
(100μl) at 37°C was added simultaneously to each well. 
After  shaking  for  5sec  to  mix,  the  optical  density  was 
monitored at 340nm every 30sec up to 30min in a BioTek 
ELx808 plate reader. The clotting time is taken as the time 
when the absorbance becomes 0.02U greater than the aver­
age  of  the  first  two  absorbance  measurements  (O'Leary 
and  Isbister,  2010). The  minimum  clotting  concentration 
(MCC5) was taken as the concentration of venom required 
to cause clotting in 5 min and was used to assess procoagu­
lant activity. Anticoagulant activity was assessed by adding 
thromboplastin (Innovin) and venom to re­calcified plasma 
to determine the anticoagulant effect of venom on thrombo­
plastin triggered clotting time compared to thromboplastin 
alone clotting time.
SDS and run for 10min at room temperature at 60V and then 
for 2hr at 100V . The molecular weight standard (Precision 
Plus Protein Standards, Dual color) was also run in parallel. 
Gels were transferred into fixative solution (40%, v/v, etha­
nol and 10%, v/v, acetic acid) for 1hr at room temperature 
on an orbital shaker. Gels were then placed in SYPRO™ 
Ruby Protein Gel Stain and allowed to incubate for 18hr 
at room temperature on an orbital shaker, after which they 
were washed in rinsing solution (10%, v/v, methanol and 
7%, v/v, acetic acid) thrice for 20min. Gels were scanned on 
Typhoon Trio Scanner (GE Healthcare, Uppsala, Sweden).
Cell culture: A7r5
Rat aorta smooth muscle cells (A7r5 cells) were cultured in 
75cm2 flasks in DMEM media supplemented with 5% (v/v) 
foetal  bovine  serum  and  1%  (w/v)  penicillin/streptomycin   
(culture media) incubated at 37°C in an atmosphere of 5% 
(v/v)  CO2. The  medium  was  replaced  every  second  day 
until cells were approximately 80% confluent (assessed by 
eye using a light microscope). Cells were then lifted using 
1ml trypsin and combined with 4ml media and pelleted by 
centrifugation at 1000rpm for 5min. The cells were resus­
pended and counted using a haemocytometer. Cells were 
subsequently seeded at 50,000 cells per well in 68­wells, in 
a 96­well cell culture plate with a final volume per well of 
100μl. The plates were incubated for 48hr at 37°C with 5%, 
v/v, CO2.
Cell proliferation assay
Cell proliferation assay was performed using the CellTiter 
96® AQueous One Solution Cell Proliferation Assay (MTS) 
(Promega, Wisconsin,  USA)  according  to  manufacturer’s 
instructions. Briefly, media was removed from wells in A7r5 
cell culture plates and the wells were washed once with pre­
warmed PBS. H. hypnale, H. nepa and H. zara venom stock 
solutions were diluted in culture media to a final concentra­
tion of 10μg/ml and subsequently serially diluted 1.2 fold, 
fifteen times (10 to 0.65μg/ml). Dilutions (100μl per well) 
were added to wells in cell culture plate in quadruplicate. 
Culture media controls (cells and media with no venom) and 
media blanks (no cells) were also run in parallel. The plates 
were incubated at 37°C with 5% (v/v) CO2 for 24hr. After 
24hr the cell culture plates were removed from the incuba­
tor and washed with pre­warmed PBS three times. 50μl of 
fresh culture media and 10μl of MTS solution were added 
to each well. The plates were further incubated at 37°C 
with 5% (v/v) CO2 for 3hr. Absorbance was measured at 
492nm utilizing fusion α plate reader (PerkinElmer). Cell 
viability was measured as a percentage of the control cells 
absorbance.
For studies with antivenom cells were grown and seeded at 
50,000 cells per well as described above, but only 28­wells 
were seeded. Plates were incubated for 48hr at 37°C with 
5%  (v/v)  CO2.  Cell  proliferation  assays  were  performed 
as described above, however a constant concentration on 
venom (5μg/ml) was added to the culture media. The culture 
media was further supplemented with antivenom at con­
centrations ranging from 4 to 0.5 times the manufacturer’s 
recommended dose for Russell’s viper or cobra venom, and 
each antivenom concentration was added in quadruplicate 
to the wells. Control wells (no antivenom) and media blanks 
(no cells) were also run in parallel. After 24hr, wells were ©The Author(s) | Journal of Venom Research | 2011 | Vol 2 | 17-23 | OPEN ACCESS  20
Solutions of the Hypnale venoms (10μg/ml) in 50μl TBS 
were added to a solution of antivenom (4mg/ml) in 50μl 
TBS and the mixtures were incubated for 30min at 37°C. 
Re­calcified plasma (100μl) was then added, and the proce­
dure followed as above. Clotting studies were also repeated 
using venom treated with pBPB.
Phospholipase A2 assay
Phospholipase  A2  activity  of  the  venoms  was  measured 
using the sPLA2 assay kit according to the manufacturer’s 
instructions. Activities were measured at a minimum of two 
concentrations of venom.
Analysis
One­way  analysis  of  variance  (ANOVA)  followed  by  a 
Bonferroni’s mulitple comparisons test was used to com­
pare  samples  for  both  cell  culture  assays  and  in  vitro 
neuro  toxicity and myotoxicity. Statistical significance was 
indicated by P<0.05. All analyses and graphics were done 
in GraphPad Prism version 5.03 for Windows, GraphPad 
Software, San Diego California USA, www.graphpad.com.
RESULTS
Reverse-Phase High Performance Liquid  
Chromatography (rpHPLC)
RP­HPLC analysis of the venoms produced similar profiles 
for H. hypnale and H. nepa venoms while the profile for 
H. zara was different. There were six groups of peaks for 
H. hypnale and H. nepa venoms and five for H. zara venom 
(Figure 1) with the venoms eluting between 45 and 60min. 
Fractions in the regions designated A, B, C, D and E 
(Figure 1) were collected and tested for clotting activity.
SDS-PAGE
The electrophoretic profiles indicated that the three venoms   
studied contained proteins ranging from ~10kDa to ~100kDa, 
and were similar to each other, with the main differences 
being quantitative (in the region of ~30kDa to ~80kDa) rat­
her than qualitative (indicated by arrows). All of the venoms 
showed a strongly staining band at ~25kDa and ~50kDa. In 
addition, H. nepa showed another strongly staining band at 
~35kDa (indicated by arrow) (Figure 2).
In vitro cytotoxicity study
All three species of Hypnale inhibited cell proliferation in 
the A7r5 cell culture with similar IC50 values of 2.07μg/ml, 
2.22μg/ml  and  2.82  μg/ml,  respectively  for  H.  hypnale, 
H. nepa and H. zara venoms (Figure 3). The addition of 
antivenom, at concentrations ranging from 0.5 to 4 times 
the recommended dose failed to negate the inhibition of 
cell proliferation caused by 5μg/ml H. hypnale, H. nepa or 
H. zara venoms (Figure 4). Addition of antivenom to culture 
media did not cause a change in absorbance readings (data 
not shown).
In vitro neurotoxicity and myotoxicity in chick biventer 
cervicis preparations
All three Hypnale venoms displayed neurotoxicity (Figure 5A) 
and myotoxicity (Figure 5B) as indicated by partial block­
ade of indirect and direct twitches, respectively, in the skel­
etal muscle preparation. Responses to exogenous ACh and 
Figure 1. Reverse phase high­peformance liquid chromatogram 
(RP­HPLC) chromatogram of (A) H. hypnale, (B) H. nepa and 
(C) H. zara using a Phenomenex Jupiter C18 column (5μ 300A 
250x4.6mm) with mobile phase 15% (v/v) acetonitrile containing 
0.1% (v/v) trifluoracetic acid, increasing to 70% acetonitrile by 












mass (KDa) H. hypnale H. nepa H. zara
Figure 2. Electrophoretic profile of H. hypnale. H. nepa 
and H. zara venom. Molecular weight maker (7μg) where 
loaded in lane 1and venom (25μg) were loaded loaded onto 
lanes 2­10 of a 12% (w/v) polyacrylamide gel. The arrows 
indicate quantitative differences in band intensities among 
the venoms.©The Author(s) | Journal of Venom Research | 2011 | Vol 2 | 17-23 | OPEN ACCESS  21
CCh were significantly inhibited by all venoms indicating a 
post­synaptic site of action (data not shown).
In vitro coagulation assay
All three Hypnale venoms had weak procoagulant activity 
with MCC5 of 4.4μg/ml, 5.6μg/ml and 5.5μg/ml of plasma, 
respectively for H. hypnale, H. nepa and H. zara venoms. 
The procoagulant activity of all 3 Hypnale venoms at 5μg/
ml  was  not  neutralised  by  pre­mixing  with  polyvalent 
antivenom at a concentration of 2000μg/ml of plasma. This 
amount of antivenom was sufficient to prevent clotting by 
Russell’s viper venom at 250ng/ml of plasma. The addi­
tion of pBPB to H. hypnale did not neutralize procoagulant 
activity. Hypnale venoms were able to clot plasma that had 
not been re­calcified. Clotting activity was only found in the 
“C” region of peaks for all three species and in region “D” 
for H. hypnale and H. zara venoms.
Phospholipase A2 (PLA2) activity
PLA2 activity was detected in all venoms with values of 
0.3, 0.2 and 0.2nmol of product/ml/min/ng being obtained 
for H. hypnale, H. nepa and H. zara, respectively. Treat­
ment  of  H.  hypnale  venom  with  pBPB  neutralised  the 
PLA2 activity.
DISCUSSION
We have demonstrated that the three Hypnale venoms have 
similar chromatographic profiles and bioactivity based on 
a number of different assays with only minor differences 
between species. The Hypnale venoms all had cytotoxicity 
but  less  potent  neurotoxicity,  myotoxicity  and  procoagu­
lant activity. The predominant cytotoxicity of the Hypnale 
venoms  is  consistent  with  Hypnale  envenoming  which 
causes local effects in 91% of cases (Ariaratnam et al, 2008;   
Ariaratnam et al, 2009). The lack of other toxicity is con­
sistent with major systemic clinical effects being less com­
mon for Hypnale compared to other medically important 
snakes in Sri Lanka (Sellahewa and Kumararatne, 1994; 
Premawardena, 1998; Ariaratnam et al, 2008; Ariaratnam   
et al, 2009). Antivenom did not neutralize the procoagulant 
effects which is the commonest systemic effect reported 
(Ariaratnam et al, 2009). 
The  chromatographic  profile  of  the  three  whole  venoms 
demonstrates they have a similar composition with five well 
defined common regions (A, B, C, D and E) with similar 
retention times (Figure 1). The main difference is in region 
D which is less prominent in H. nepa. Clotting activity was 
found in regions C of all three venoms and region D of 
H. hypnale and H. zara showing the presence of more than 
one procoagulant.
The Hypnale venoms had low IC50 values of between 2 and 
3μg/ml compared to cytotoxic Naja mossambica with an 
IC50 of 7.9μg/ml and Australasian death adders with IC50 
ranging from 47.7 to 107.4μg/ml (Kalam et al, 2010). Such 
low IC50 suggest that they contain more potent cytotoxins 
than other snake venoms. This is supported by a recent study 
demons  trating necrotic activity of Hypnale venom (Tan et al, 
2011). However, Hypnale venoms were much less neuro­
toxic and myotoxic compared to elapid snakes known to 
cause  clinically  important  neurotoxicity  and  myotoxicity, 
consistent with the lack of neurotoxicity and myotoxicity 
reported for Hypnale. 
Although  Hypnale  venoms  were  procoagulant  they  were 
much less potent than Russell’s viper venom or Australasian   
elapid  venoms  [MCC5  0.0005­0.02μg/ml]  (Isbister  et  al, 
2010; O'Leary and Isbister, 2010). Coagulopathy is reported 
less in Hypnale envenoming (Sellahewa and Kumararatne, 
1994; Premawardena, 1998; Ariaratnam et al, 2009), which 
is consistent with the limited procoagulant effect demon­
strated in this study. The procoagulant effect is not neutral­
ized by antivenom at concentrations used for patients with 
envenoming from other snakes consistent with antivenom 
not  being  raised  against  Hypnale  venom.  In  addition,  it 
is not neutralized by pBPB treatment suggesting the pro­
coagulant toxin in the venom is not a phospholipase. De 
Silva et al, (1994) demonstrated thrombin­like activity and 
weak fibrinolysis action of H. hypnale venom. 
Figure 3. Sigmoidal growth curves of H. hypnale (filled 
circle), H. nepa (open circle) or H. zara (open triangle) 
venoms, displayed as percentage of maximum cell viability 
in A7r5 cells (n=3).
Figure 4. Cell proliferation of A7r5 cells treated with 5μg/ml 
of H. hypnale (small cross hatching), H. nepa (large cross 
hatching) or H. zara (horizontal lines) venoms and varying 
polyvalent antivenom concentrations (n=4).©The Author(s) | Journal of Venom Research | 2011 | Vol 2 | 17-23 | OPEN ACCESS  22
Figure 6. Procoagulant effects of Hypnale venoms. Clotting 
times for increasing concentrations of H. hypnale, H. nepa or 
H. zara venoms in the absence of another triggering agent  
showing the procoagulant activity.
Previous studies of Hypnale venom have only investigated 
the PLA2 activity of H. hypnale venom with no previous 
studies  on  H.  nepa  and  H.  zara  venom  (De  Silva  et  al, 
1994;  Wang  et  al,  1999). This  study  has  demonstrated 
PLA2 activity in all three Hypnale venoms and shown that 
this activity is neutralized pBPB. Four PLA2 isoforms 
previously  isolated  from  H.  hypnale  had  strong  heparin 
binding ability and induced oedema. 
Another  recent  study  investigated  the  efficacy  of  Indian 
polyvalent  and  monovalent  and  polyvalent  Malayan  Pit 
Viper (Calloselasma rhodostoma) antivenoms against the 
in vitro effects of H. hypnale venoms (Tan et al, 2011). Simi­
lar to our study they found that Bharat polyvalent antivenom 
did not protect mice from H. hypnale venom. However, they 
demonstrated  cross­neutralisation  with  monovalent  and 
polyvalent  antivenoms  from  the Thai  Red  Cross  Society 
raised against C. rhodostoma (Tan et al, 2011). This is most 
likely because C. rhodostoma is closely related to Hypnale 
and is regarded as a sister taxon. 
The use of venom dried using silica gel may be associated 
with degradation of some components of the venom. How­
ever, studies of dessicated venom suggest this occurs for 
long periods of storage and in our study the venom was used 
within 12 months of collection (Schöttler, 1951).
This  study  demonstrates  that  cytotoxicity  appears  to  be 
the most potent effect of Hypnale venoms and they have 
mild procoagulant activity, both consistent with their clini­
cal effects. The study represents the first investigation and 
characterization  of  biochemical  and  biological  properties   
Figure 5. The effects of H. hypnale, H. nepa or H. zara venoms (10μg/ml; n=3) on (A) indirect (i.e., nerve mediated) 
twitches and, (B) direct (i.e., muscle mediated) twitches of the chick biventer cervicis nerve­muscle preparation.©The Author(s) | Journal of Venom Research | 2011 | Vol 2 | 17-23 | OPEN ACCESS  23
of  the  venoms  from  H.  nepa  and  H.  zara.  Finally  the 
study  shows  that  Indian  polyvalent  antivenom  raised 
against Naja naja, Daboia russellii, Bungarus caeruleus 
and Echis carinatus did not neutralize the venom effects 
consistent with previous studies (Tan et al, 2011). 
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